A Fairer Playing Field
Enforcing antitrust and merger rules. A recently published report shows how the European Commission has protected patients against anticompetitive practices over the last decade.
Maryam Mahdi |
Mergers and acquisitions drive the growth of companies within a competitive market, but when do these deals become damaging to a healthy market?
According to EU law, the point of harm officially occurs when anticompetitive practices result in the dominance of particular companies within the market and prevent patients’ from accessing the cheapest and most innovative pharmaceutical products. Prior to the European Commission’s inquiry into the pharmaceutical sector in 2009, anti-competitive practices were rife within the pharma industry, limiting patients’ inherent rights to such products.
In January of this year, the European Commission (EC) published a report detailing how active competition law enforcement helped to protect patients’ rights across the EU region between 2009 and 2017. Though EU competition laws did much to protect against dominance in the pharmaceutical market, they did not previously cover some of the anticompetitive practices some pharma companies were engaging in.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.